Literature DB >> 30831262

Strategies for the discovery of biased GPCR ligands.

Marcel Bermudez1, Trung Ngoc Nguyen2, Christian Omieczynski2, Gerhard Wolber2.   

Abstract

G-protein-coupled receptors (GPCRs) represent important drug targets with complex pharmacological characteristics. Biased signaling represents one important dimension, describing ligand-dependent shifts of naturally imprinted signaling profiles. Because biased GPCR modulators provide potential therapeutic benefits including higher efficiencies and reduced adverse effects, the identification of such ligands as drug candidates is highly desirable. This review aims to provide an overview of the challenges and strategies in the discovery of biased ligands. We show different approaches for biased ligand discovery in the example of G-protein-biased opioid analgesics and discuss possibilities to design biased ligands by targeting extracellular receptor regions.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2019        PMID: 30831262     DOI: 10.1016/j.drudis.2019.02.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  10 in total

1.  Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors.

Authors:  Michael L Garelja; Maggie Au; Margaret A Brimble; Joseph J Gingell; Erica R Hendrikse; Annie Lovell; Nicole Prodan; Patrick M Sexton; Andrew Siow; Christopher S Walker; Harriet A Watkins; Geoffrey M Williams; Denise Wootten; Sung H Yang; Paul W R Harris; Debbie L Hay
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-26

Review 2.  Biased signaling in naturally occurring mutations of G protein-coupled receptors associated with diverse human diseases.

Authors:  Li-Kun Yang; Zhi-Shuai Hou; Ya-Xiong Tao
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-09-17       Impact factor: 5.187

Review 3.  Trends in application of advancing computational approaches in GPCR ligand discovery.

Authors:  Siyu Zhu; Meixian Wu; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-27

4.  Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt1]DALDA, and KGOP01, Binding to the mu Opioid Receptor.

Authors:  Maria Dumitrascuta; Marcel Bermudez; Steven Ballet; Gerhard Wolber; Mariana Spetea
Journal:  Molecules       Date:  2020-04-29       Impact factor: 4.411

5.  Biased Ligands Differentially Shape the Conformation of the Extracellular Loop Region in 5-HT2B Receptors.

Authors:  Katrin Denzinger; Trung Ngoc Nguyen; Theresa Noonan; Gerhard Wolber; Marcel Bermudez
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

6.  Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the µ-, δ-, κ-Opioid and Nociceptin Receptors.

Authors:  Kristina Puls; Helmut Schmidhammer; Gerhard Wolber; Mariana Spetea
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411

Review 7.  Biased Opioid Ligands: Revolution or Evolution?

Authors:  Florence Noble; Nicolas Marie
Journal:  Front Pain Res (Lausanne)       Date:  2021-09-24

Review 8.  Biased agonism at β-adrenergic receptors.

Authors:  Michael Ippolito; Jeffrey L Benovic
Journal:  Cell Signal       Date:  2020-12-29       Impact factor: 4.315

9.  Development of a Testing Funnel for Identification of Small-Molecule Modulators Targeting Secretin Receptors.

Authors:  Daniela G Dengler; Qing Sun; John Holleran; Sirkku Pollari; Jannis Beutel; Brock T Brown; Aki Shinoki Iwaya; Robert Ardecky; Kaleeckal G Harikumar; Laurence J Miller; Eduard A Sergienko
Journal:  SLAS Discov       Date:  2020-08-04       Impact factor: 3.341

10.  Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists.

Authors:  Teresa Kaserer; Theresa Steinacher; Roman Kainhofer; Filippo Erli; Sonja Sturm; Birgit Waltenberger; Daniela Schuster; Mariana Spetea
Journal:  Sci Rep       Date:  2020-08-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.